Pathway Therapeutics pathwaytx.com

Pathway Therapeutics is a clinical stage, privately held, pharmaceutical company developing differentiated isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. The company's lead product, PWT33597, is a balanced, dual PI3K alpha/mTOR inhibitor and the first compound with this profile to enter the clinic. Dual inhibition of PI3K and mTOR shuts down the PI3K/mTOR pathway more effectively than single target inhibitors. Of the four PI3K isoforms, PI3K...Show all

Pathway Therapeutics is a clinical stage, privately held, pharmaceutical company developing differentiated isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. The company's lead product, PWT33597, is ...Show all

Company (Alive / Active)

All investors data 5 Investors

• Breast Cancer Research Trust
• CM Capital
• GBS Venture Partners
• New Zealand Venture Investment Fund
• Trans Tasman Commercialisation Fund

Board Members

Competitors

Patents